New Hope for Chronic Myelogenous Leukemia

Susan Farley
Published Online: Friday, April 1, 2005

The compound AMN107 has been shown to be more effective than Gleevec for the first-line treatment of chronic myelogenous leukemia (CML) according to recent data from researchers at the Dana-Farber Cancer Institute and scientists at Novartis AG in Switzerland. Researchers involved in the study were aiming to find a comparable drug to Gleevec for the treatment of CML, but one that targeted more of the cancer cells. According to a recent article in Cancer, AMN107 is 20 times more potent than Gleevec. Lead author Dr. James Griffin of the Dana-Farber Cancer Institute said, "While?approximately 95% of patients treated with Gleevec achieve remission, there clearly is a need for therapies that produce longer remissions, are active against advanced disease, and can be used when Gleevec loses effectiveness."

Ms. Farley is a freelance medical writer based in Wakefield, RI.



Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$
VSEO N/A